DANIEL LYNCH: Open Payments
NPI 1174071575 · MOORESTOWN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$665 in 37 payments from 14 companies in 2025. Trend: 2023 $448 · 2024 $771 · 2025 $665
Food & beverage: $665
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $186 |
| Novo Nordisk Inc | 6 | $116 |
| ABBVIE INC. | 5 | $87 |
| GlaxoSmithKline, LLC. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| PFIZER INC. | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
Products named: BREZTRI, UBRELVY, AIRSUPRA, SHINGRIX, REXULTI, Rybelsus, VRAYLAR, Wegovy.
Industry payments across NJ — which companies pay providers there.
